- Home
- PGEN vs FLNC Comparison
PGEN vs FLNC Comparison
Compare PGEN & FLNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | FLNC |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGEN | FLNC |
|---|---|---|
| Price | $6.25 | $14.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 17 |
| Target Price | $8.33 | ★ $15.71 |
| AVG Volume (30 Days) | 3.7M | ★ 7.3M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $230,981,000.00 | ★ $2,262,830,000.00 |
| Revenue This Year | $1,115.92 | $51.23 |
| Revenue Next Year | $81.04 | $21.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.70 | $6.60 |
| 52 Week High | $6.04 | $33.51 |
Technical Indicators
Market Signals| Indicator | PGEN | FLNC |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 40.75 |
| Support Level | $3.96 | $11.88 |
| Resistance Level | $6.04 | $13.92 |
| Average True Range (ATR) | 0.31 | 1.10 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 79.59 | 43.76 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About FLNC Fluence Energy Inc.
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.